- Home
- PDSB vs AGEN Comparison
PDSB vs AGEN Comparison
Compare PDSB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- AGEN
- Stock Information
- Founded
- PDSB 2005
- AGEN 1994
- Country
- PDSB United States
- AGEN United States
- Employees
- PDSB N/A
- AGEN N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDSB Health Care
- AGEN Health Care
- Exchange
- PDSB Nasdaq
- AGEN Nasdaq
- Market Cap
- PDSB 84.2M
- AGEN 96.2M
- IPO Year
- PDSB N/A
- AGEN 2000
- Fundamental
- Price
- PDSB $1.45
- AGEN $3.48
- Analyst Decision
- PDSB Strong Buy
- AGEN Buy
- Analyst Count
- PDSB 3
- AGEN 3
- Target Price
- PDSB $14.00
- AGEN $10.50
- AVG Volume (30 Days)
- PDSB 296.4K
- AGEN 419.4K
- Earning Date
- PDSB 11-14-2024
- AGEN 03-13-2025
- Dividend Yield
- PDSB N/A
- AGEN N/A
- EPS Growth
- PDSB N/A
- AGEN N/A
- EPS
- PDSB N/A
- AGEN N/A
- Revenue
- PDSB N/A
- AGEN $160,427,000.00
- Revenue This Year
- PDSB N/A
- AGEN N/A
- Revenue Next Year
- PDSB N/A
- AGEN $36.13
- P/E Ratio
- PDSB N/A
- AGEN N/A
- Revenue Growth
- PDSB N/A
- AGEN 59.00
- 52 Week Low
- PDSB $1.30
- AGEN $2.50
- 52 Week High
- PDSB $6.68
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- PDSB 34.16
- AGEN 58.60
- Support Level
- PDSB $1.37
- AGEN $3.08
- Resistance Level
- PDSB $1.50
- AGEN $3.29
- Average True Range (ATR)
- PDSB 0.13
- AGEN 0.26
- MACD
- PDSB 0.00
- AGEN 0.05
- Stochastic Oscillator
- PDSB 28.03
- AGEN 80.36
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).